Olema Pharmaceuticals, Inc.
NASDAQ:OLMABiotechnology
-$0.26 today
- Market cap
- $618.50M
- Beta
- 2.00
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$1.80
Volume 1.18M
Average 1.27M
OLMA Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Olema Pharmaceuticals, Inc.NASDAQ: OLMA
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow turns positive
Q1 FY2026 investing cash flow was $4.53M, compared with -$45.08M a year earlier. Trailing-twelve-month investing cash flow was -$106.15M.
Context
- Investing cash flow increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly investing cash flow holds near $4.53M or moves back toward the trailing-twelve-month quarterly average of -$26.54M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (155.76M) USD
- Year-over-year change
- -66.5%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (155.76M) | -66.5% |
| FY2024 | 2024-12-31 | (93.53M) | -1828.0% |
| FY2023 | 2023-12-31 | (4.85M) | -105.3% |
| FY2022 | 2022-12-31 | 91.48M | +133.2% |
| FY2021 | 2021-12-31 | (275.44M) | — |
Investing Cash Flow vs competitors
How OLMA compares with its peers on the latest reported figures
- OLMA's LTM Mar 2026 investing cash flow of $106.15M is the largest of the 2 companies compared; the peer median is $35.25M.
- Its year-over-year change of -10.4% is the highest of 2, against a peer median of -20472.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $106.15M | -10.4% | — | — | |
| LTM Mar 2026 | $35.25M | -20472.8% | — | 15.5% | |
| Peer median (excluding OLMA) | $35.25M | -20472.8% | — | 15.5% | |
Competitors are the stored peer set for OLMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.1M) | (104.79M) | (96.66M) | (129.47M) | (162.45M) |
| Depreciation & Amortization | 1.66M | 1.66M | 377K | 393K | 490K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 17.26M | 22.58M | 17.59M |
| Change in Working Capital | 2.83M | 3.02M | (589K) | 9.16M | 2.78M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (683K) | 351K | 2.32M | 2.51M | 4.6M |
| Other Working Capital | 3.51M | 2.67M | (2.91M) | 6.65M | (1.82M) |
| Other Non-Cash Items | 15.91M | 18.04M | (4.12M) | (7.02M) | (5.12M) |
| Operating Cash Flow | (50.69M) | (82.07M) | (83.73M) | (104.35M) | (146.72M) |
| Capital Expenditures | (1.58M) | (363K) | 0 | (159K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (486.97M) | (213.66M) | (255.63M) | (394.96M) | (500.72M) |
| Sales of Investments | 213.1M | 305.5M | 250.76M | 301.59M | 344.96M |
| Other Investing Activities | 0 | 0 | 14K | 0 | 0 |
| Investing Cash Flow | (275.44M) | 91.48M | (4.85M) | (93.53M) | (155.76M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 3M |
| Common Stock Issued | 1.39M | 476K | 129.74M | 266.29M | 208.3M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 3.68M | 2.53M | 0 |
| Financing Cash Flow | 1.39M | 476K | 133.42M | 268.82M | 211.3M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (324.74M) | 9.89M | 44.84M | 70.94M | (91.18M) |
| Free Cash Flow | (52.27M) | (82.43M) | (83.73M) | (104.51M) | (146.72M) |
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
Intrinsic Alpha fair value
Locked
Current Price
$7.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.